Baqsimi ® (glucagon) nasal powder

3mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can Baqsimi™ (glucagon) nasal powder be used during pregnancy or lactation?

No clinical studies with Baqsimi have been performed in pregnant women or nursing mothers.

US_cFAQ_NG037_PREGNANCY_LACTATION
US_cFAQ_NG037_PREGNANCY_LACTATION
en-US

Use in Pregnancy and Lactation

No clinical studies with Baqsimi have been performed in pregnant women or nursing mothers.

Pregnancy

Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified

  • a drug-associated risk of major birth defects
  • miscarriage, or
  • adverse maternal or fetal outcomes.1

Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation.1

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.1

Animal Data

In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m2) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality.1

Lactation

There is no information available on the

  • presence of glucagon in human or animal milk
  • effects of the drug on the breastfed infant, or
  • effects of the drug on milk production.1 

However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is, therefore, unlikely to cause harm to an exposed infant.1

Reference

1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Date of Last Review: February 07, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical